Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of Brimonidine Posterior Segment Drug Delivery System in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration

Trial Profile

Safety and Efficacy of Brimonidine Posterior Segment Drug Delivery System in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brimonidine (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms BEACON
  • Sponsors Allergan
  • Most Recent Events

    • 29 Aug 2018 Status changed from active, no longer recruiting to discontinued.
    • 13 Apr 2018 This trial was Completed in Germany (End date: 2018-03-30), according to European Clinical Trials Database.
    • 23 Feb 2018 This trial was Discontinued in Italy, according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top